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Background: Polyunsaturated fatty acids (PUFAs) may protect against metabolic diseases. Although the benefits of
the n-3 family of PUFA have been well investigated in nonalcoholic steatohepatitis (NASH), little is known about the
effect of the n-6 family. This study examined the effect of linoleate, a member of the n-6 family, on regulation of
the palmitate-induced inflammatory cytokine interleukin-8 (IL8) in hepatocytes.
Methods: Huh7 cells and HepG2 cells were cultured with and without free fatty acid treatment (palmitate and
linoleate, alone or in combination, 100–1000 μM). Inflammatory pathways, lipid accumulation, apoptosis and cell
viability were monitored.
Results: Dose- and time-related changes of IL8 mRNA expression were examined and 9 h treatment with 500 μM
palmitate showed the greatest elevation of IL8. Co-treatment with 500 μM palmitate and 400 μM linoleate significantly
suppressed IL8 production below that with palmitate alone in both cells (both mRNA and protein). A quantitative
measurement for lipid accumulation showed no significant difference between palmitate-treated cells (1.69 ± 0.21),
linoleate-treated cells (1.61 ± 0.16) and palmitate and linoleate-treated cells (1.73 ± 0.22, NS, n = 7). The co-treatment
with 400 μM linoleate inhibited phospho-c-Jun N-terminal kinase (pJNK) activation and IkBα reduction caused by
500 μM palmitate treatment. Treatment with 400 μM linoleate alone led to IL8 production (5.48 fold change), similar
to co-treatment, with no influence on the expression of pJNK/IkBα. The cell viability was similar between treatment
with 500 μM palmitate and with both 500 μM palmitate and 400 μM linoleate, showing no significant changes in the
expression of cleaved caspase-3.
Conclusions: Linoleate is a potent regulator of the proinflammatory cytokine IL8 via the JNK and nuclear factor kappa
B pathways that are involved in the pathophysiology of NASH, suggesting a future recommendation of dietary
management.
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Nonalcoholic fatty liver disease (NAFLD) is increasing
worldwide as a leading cause of chronic liver damage
[1,2]. It is closely associated with obesity, diabetes and
hyperlipidemia [3-5]. Insulin resistance, endoplasmic
reticulum (ER) stress, inflammation, and oxidative stress
have been identified as underlying features in the deve-
lopment of nonalcoholic steatohepatitis (NASH), al-
though the precise mechanisms remain unclear [6,7].
Elevated free fatty acids (FFAs) are considered to be a
major cause of injury and death of liver cells in NASH* Correspondence: maru-cib@umin.ac.jp
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article, unless otherwise stated.[7,8]. Recent studies have shown differences between
controls and patients with NAFLD/NASH in the content
of FFA in the serum and liver [9,10], probably caused by
an imbalance of dietary intake and/or impaired metabo-
lism [11]. Furthermore, changes in the FFA content of
the liver may affect lipid metabolism and inflammation.
Influences of saturated fatty acids, as typified by pal-
mitate, may account for the liver cell damage which con-
tributes to developing NASH, characterized by saturated
FFA-induced lipotoxicity [8], lipoapoptosis [12] and in-
sulin resistance [13]. Inflammation may also be a major
cause of NASH. Lipopolysaccharide (LPS), a gut-derived
toll-like receptor 4 ligand, enhances liver injury and in-
creases inflammatory cytokine induction in a NASHtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Maruyama et al. Lipids in Health and Disease 2014, 13:78 Page 2 of 8
http://www.lipidworld.com/content/13/1/78model, suggesting the features of a first and second hit lead-
ing to the development of NASH [14]. Another study re-
ported that palmitate activates the inflammasome and
induces sensitization to LPS-induced interleukin 1β
(IL1β) release by hepatocytes [15]. Furthermore, palmi-
tate triggers the release of danger signals from hepato-
cytes in a caspase-dependent manner.
A production of IL8, a proinflammatory cytokine, may
be closely involved in the pathogenesis of NASH [16].
IL-8 is produced in response to inflammatory mediators,
such as IL1α, IL1β, and tumor necrosis factor (TNF) in
hepatocytes [17], and its production is dependent on nu-
clear factor kappa B (NFkB) and c-Jun N-terminal kinase
(JNK) [16]. Palmitate-induced IL8 production may also
be closely associated with the development of diabetes
[18]. Palmiate also induces IL-6 via NFkB in adipocytes
[19].
The n-3 and n-6 polyunsaturated fatty acids (PUFAs)
offer protective effects against metabolic abnormalities [9].
The benefits of n-3 family of PUFA are well-known, they
protect against the adverse symptoms of metabolic syn-
drome and reduce the risk of heart disease [20]. Mean-
while, recent double-blind study has shown that daily
supplementation with 1 g of n-3 FAs did not reduce the
rate of cardiovascular events in patients at high risk for
the event during a median follow-up periods of 6.2 years
[21]. Anyhow, there are many studies which focused on
the effects of n-3 PUFA. However, little is known about
the effects of the n-6 family of PUFA against metabolic
diseases. Linoleate is a member of the n-6 family and a
major component of plant oil; sunflower, soybean and saf-
flower oils contain more than 50% linoleate [22]. It is also
present in fish oil, along with the omega-3 family which is
the principal component [23].
Here, we have designed a study to explore the potential
effect of linoleate in the regulation of the inflammatory
cytokine IL8 in Huh7 cells and HepG2 cells. The aims of
the study were: 1) to examine the dose-dependent effect
of linoleate in the regulation of this proinflammatory
cytokine, 2) to examine the effect of linoleate on the
palmitate-induced lipid accumulation, 3) to determine
the cellular outcomes of co-treatment with palmitate
and linoleate 4) and to determine the pathways involved
in the regulation of the palmitate-induced proinflamma-
tory cytokine by linoleate treatment.
Results
IL8 expression in FFA treated Huh-7 cells
Time and dose dependent changes of IL8 expression after
palmitate treatment
Time- and dose-related changes of IL8 in HepG2 cells
were reported in a previous study [16]. The current study
detected the time-related changes of IL8 mRNA expres-
sion in Huh7 cells following treatment with 500 μMpalmitate, this dose being based on data in the literatures
[24,25]. IL8 expression was highest after 9 hours of treat-
ment, being 92.1 fold greater than the control (Huh7 incu-
bated with bovine serum albumin) (Figure 1A). IL8
expression after 9 hours of palmitate treatment showed
dose-related changes, the highest expression being with
500 μM palmitate treatment (104.9 fold greater than the
control) (Figure 1B).
Dose dependent changes of IL8 after linoleate treatment
According to the results of palmitate treatment, IL8
mRNA expression due to linoleate treatment was also
assessed after 9 hours of treatment. IL8 expression in-
creased 5.2 to 11.7 fold with doses from 100 to 800 μM,
however, it increased markedly by 53.8 fold at 900 μM
and 41.9 fold at 1000 μM (Figure 1C). No expression of
TNFα mRNA was detected in cells treated with palmi-
tate or linoleate (Data are not shown).
Lipid accumulation in Huh7 cells after 9 hours of
treatment with FFA
Lipid accumulation was detected in Huh7 cells by stain-
ing with Oil Red O. The images were captured by mi-
croscopy at a magnification of 20× (Figure 2).
A quantitative measurement for lipid accumulation
showed no significant difference between palmitate-
treated cells (1.69 ± 0.21), linoleate-treated cells (1.61 ±
0.16) and palmitate and linoleate-treated cells (1.73 ±
0.22, NS, n = 7).
Changes of IL8 expression after co-incubation with palmi-
tate and linoleate in Huh-7 cells and HepG2 cells
The dose-related effect of linoleate in regulating palmitate-
induced IL8 production was assessed by 9 hours of co-
incubation with 500 μM palmitate and 100–1000 μM
linoleate (Figure 3A). The expression of IL8 mRNA
showed dose-related effects from 5.6 to 17.9 fold above
the control (Huh7 incubated with bovine serum albu-
min) and 400 μM linoleate provided the most significant
effect in suppressing IL8 expression (5.6 fold change).
Increased IL8 expression was significantly suppressed
by co-treatment with palmitate and linoleate (7.33 fold
change) compared to treatment with palmitate alone
(133.5 fold change, p < 0.0001, n = 6) (Figure 3B) in
Huh7 cells. Treatment with 400 μM linoleate alone in-
creased IL8 expression (5.48 fold change) to a level
similar to that with co-treatment in Huh7 cells.
As the increase of IL8 according to the incubation
time and dose of palmitate treatment in HepG2 cells is
well-known [16], the effect to co-incubation with palmi-
tate and linoleate on the IL8 expression was also exam-
ined in HepG2 cells. The suppression of IL8 mRNA was
detected by the addition of linoleate (Figure 3C). A
300 μM linoleate showed maximum suppression with
Figure 1 Dose- and time-related changes of IL8 mRNA expression following free fatty acid treatment. 1a. Expression of IL8 following
500 μM palmitate treatment, showing the highest expression with 9 hours of treatment (92.1 fold greater than the control, Huh7 cells incubated
with bovine serum albumin; n = 4, *p < 0.0001). b. Expression of IL8 after 9 hours of treatment with palmitate, showing dose-related changes with
the highest expression of IL8 following treatment with 500 μM palmitate (104.9 fold greater than the control, Huh7 cells incubated with bovine
serum albumin; n = 4, *p < 0.01). c. Expression of IL8 after 9 hours of treatment with linoleate, showing dose-related changes. Expression of IL8
was 5.2 to 11.7 fold increase from 100 to 800 μM, however, it increased markedly at 900 μM with a 53.8 fold increase and 1000 μM with a 41.9
fold increase (n = 4, *p < 0.01).
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cells treated by 500 μM palmiate alone.
Production of IL8 due to the FFA treatment
The IL8 production was assessed by enzyme-linked im-
munosorbent assay (ELISA) in both Huh-7 cells and
HepG2 cells. The IL8 release increased by palmitate
treatment alone compared to untreated cells. The IL8
production was significantly reduced by the co-
incubation with linoleate compared to the cells treatedFigure 2 Lipid accumulation in Huh7 cells. Lipid accumulation was dete
captured by microscopy at a magnification of 20×. a. Untreated cells. b. Ce
9 hours of treatment with 400 μM linoleate. d. Cells after 9 hours of treatmby palmitate alone; with 400-1000 μM linoleate in the
Huh7 cells, and with 100-900 μM linoleate in the
HepG2 cells (Figure 4A, B).
Cell viability with respect to FFA treatment in Huh7 cells
There was no significant difference in the viability be-
tween cells treated with 500 μM palmitate alone (75 ±
5.6%) and cells treated by co-incubation with 500 μM
palmitate and 400 μM linoleate (69.8 ± 7.7%; n = 6, p =
0.21). However, the viability of cells treated with a highcted in Huh7 cells by staining with Oil Red O. The images were
lls after 9 hours of treatment with 500 μM palmitate. c. Cells after
ent with both 500 μM palmitate and 400 μM linoleate.
Figure 3 Changes of IL8 mRNA expression following co-incubation with palmitate and linoleate. A. Dose-related changes of IL8 expression
following co-incubation with 500 μM palmitate and linoleate (100 to 1000 μM) in Huh7 cells. Dose-related effect of linoleate in the regulation
of palmitate-induced IL8 production was assessed following 9 hours of incubation. A 400 μM linoleate showed maximum suppression (n = 4,
*p < 0.05). B. Suppressive effect of linoleate against IL8 production induced by palmitate in Huh7 cells. IL8 mRNA expression was significantly
lower following co-incubation with palmitate and linoleate (7.33 fold increase; greater than the control, Huh7 cells incubated with bovine serum
albumin) than those with palmitate treatment alone (133.5 fold increase, n = 6, *p < 0.0001). A co-incubation with 400μM linoleate showed
suppression of IL8 expression with 94.5% decrease compared to the cells treated by 500μM palmitate alone. C. Dose-related changes of IL8
expression following co-incubation with 500 μM palmitate and linoleate (100 to 1000 μM) in HepG2 cells. Dose-related effect of linoleate in the
regulation of palmitate-induced IL8 production was also assessed following 9 hours of incubation in HepG2 cells. A 300 μM linoleate showed
maximum suppression with 87.1% decrease compared to the IL8 expression in the cells treated by 500 μM palmiate alone (n = 4, *p < 0.01).
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4% at 1000 μM) was significantly lower than that of cells
treated with a low concentration of linoleate (71.4 ± 4.8
at 100 μM; 63.3 ± 15.9% at 200 μM, n = 6, p < 0.0001).Apoptosis following FFA treatment
Caspase-3 was used as an indicator of apoptosis of
Huh-7 cells and cleaved caspase-3 was examined to de-
termine at a molecular level the presence of apoptosis
after FFA treatment. Cleaved caspase-3 showed no sig-
nificant changes in the expression after the FFA treat-
ment (n = 4), among cells treated by 500 μM palmitate,Figure 4 Assessment of IL8 production due to free fatty acid treatme
production was significantly reduced by the co-incubation with linoleate c
linoleate in the Huh7 cells. The data represent a mean value of 4 experime
palmitate alone. B. IL8 production in HepG2 cells. The IL8 production was s
the cells treated by palmitate alone; with 100-900 μM linoleate in the HepG
deviation.*p = 0.011 compared with cells treated by palmitate alone.400 μM linoleate and co-incubation with both of them
(Figure 5A).
Changes in inflammatory pathways following
FFA treatment
Previous studies have reported that pJNK activation
and reduced IkBα expression are key mechanisms for
palmitate-induced IL8 production [16,26]. Therefore,
the present study examined the relevant pathways in Huh7
cells and found the similar findings (Figure 5B, C, D, E).
Here, analysis of cytoplasmic extracts showed that co-
incubation with 500 μM palmitate and 400 μM linoleate
significantly inhibited pJNK activation and the reductionnt by commercial ELISA kit. A. IL8 production in Huh-7 cells. The IL8
ompared to the cells treated by palmitate alone; with 400-1000 μM
nts ± standard deviation. *p = 0.041 compared with cells treated by
ignificantly reduced by the co-incubation with linoleate compared to
2 cells. The data represent a mean value of 4 experiments ± standard
Figure 5 Analysis of protein expression by western blotting. A. Cleaved caspase-3. Caspase-3 was used as an indicator of apoptosis in Huh-7
cells and cleaved caspase-3 was examined after free fatty acid treatment to determine the presence of apoptosis at a molecular level. The cleaved
caspase-3 (17 kDa and 19 kDa) showed no significant changes in the expression after the FFA treatment (n = 4), among cells treated by 500 μM
palmitate, 400 μM linoleate and co-incubation with both of them. B, C, D, E. The effect of co-incubation with palmitate and linoleate on markers
of inflammation. Huh7 cells were incubated with bovine serum albumin (control) or after free fatty acid treatment (500 μM palmitate and/or
400 μM linoleate). Western blot analysis of phospho-c-Jun N-terminal kinase and total-c-Jun N-terminal kinase or β-actin (Figure 5B, 6 hr incuba-
tion), IkBα (Figure 5D, 3 hr incubation) and β-actin (internal control). The gels shown are representative of 4 independent experiments and data in
the graphs are expressed as the ratio of the target protein to total-c-Jun N-terminal kinase or β-actin (Figure 5C and 5E). The expression of pJNK
increased significantly in Huh-7 cells treated with 500 μM palmitate (64.9 ± 4.1) compared to control cells (35 ± 4.2; *p<0.05), cells treated with
both 500 μM palmitate and 400 μM linoleate (32.3 ± 2.5; *p<0.01), and cells treated with 400 μM linoleate (36.1 ± 3.3; *p<0.01; n = 4). The expres-
sion of IkBα decreased significantly in Huh-7 cells treated with 500 μM palmitate (46.6 ± 2.2) compared to control cells (68.1 ± 5.9 ; *p<0.05), cells
treated with both 500 μM palmitate and 400 μM linoleate (68.3 ± 5.7; *p<0.05), and cells treated with 400 μM linoleate (65.7 ± 3.3; *p<0.05; n = 4).
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of linoleate. However, treatment with 400 μM linoleate
alone did not affect the expression of pJNK/IkBa.
Discussion
Detailed and comprehensive analysis of the effects of FFA
on cellular pathways may provide a significant insight into
the study of NASH, a disorder caused by complicated
mechanisms. Among the complex pathways leading to
NASH, inflammation features as a major factor in the
pathogenesis of steatohepatitis [27].
The current study proved the value of linoleate as a po-
tent protector against lipotoxicity-related inflammation.
First, we reported the protective and dose-dependent effect
of co-incubation with linoleate against the increased pro-
duction of IL8 that follows palmitate treatment, showing
no additional effect on lipid accumulation. Second, wedetermined the lipotoxicity of an overdose of linoleate
(more than twice that dose giving the most beneficial ef-
fect), showing IL8 production from Huh7 cells. Third, the
study showed that linoleate has anti-inflammatory effects,
with the regulation of JNK/NFkB pathways.
A recent study has shown the effect of unsaturated
fatty acids against NLRP3 inflammasome [28], sugges-
ting the potential function of unsaturated fatty acids to
prevent inflammation.
It is clear that PUFAs provide a beneficial effect by
suppressing lipogenesis and enhancing FFA oxidation
[20], as dietary n-6 and n-3 PUFA reduce triglyceride
accumulation in skeletal muscle and, potentially, in
cardiomyocytes and beta cells [29]. PUFAs also reduce
the production of hepatic malonyl coenzyme A (CoA),
which is a negative metabolic effector of carnitine pal-
mitoyltransferase [30]. In particular, the n-3 PUFAs
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element binding protein-1 (SREBP-1), which promotes
triglyceride accumulation in the liver by the up-regulation
of lipogenic genes such as fatty acid synthase (FAS) and
sterol Co-A desaturase-1 (SCD-1). In fact, diets rich in
18 : 2 (n-6) or 20 : 5 and 22 : 6 (n-3) were found to lead to
a reduction of the hepatic nuclear and precursor content
of mature SREBP-1 by 85% and 60%, respectively [31]. It
is also known that PUFAs upregulate peroxisomal prolif-
erator activated receptor-α (PPAR-α), which stimulates
hepatic fatty acid oxidation and activates fatty acid trans-
port protein and acyl-CoA synthase. This effect is more
potent with the n-3 family than the n-6 family. Altogether,
these studies suggest that the effects of the n-3 family
seem to be dominant over those of the n-6 family in co-
ordinating the upregulation of lipid oxidation and down-
regulation of lipid synthesis. Actually, macrosteatosis
constitutes a feature of NAFLD, which is characterized by
the accumulation of triglycerides in the liver together with
a reduced hepatic content of n-3 long chain PUFAs and
an abnormally high n-6 : n-3 PUFA ratio [32].
Contrary to the beneficial aspect of PUFAs, a negative ef-
fect of linoleate has been reported on H4IIE cells [33]. The
study showed that linoleate promotes apoptosis through
the release of cytochrome C but not cleavage of caspase-3.
The authors suggested that ER stress may contribute to
fatty acid-induced apoptosis of liver cells. However, our
study showed no significant difference in the viability be-
tween cells with and without linoleate treatment, showing
no activation of caspase-3. This may be due to the differ-
ence of cells and doses of FFA, their study used rat liver
cells treated with 125–250 μM palmitate and linoleate
whose concentration was lower than that in our study.
Investigators have studied the effect of incubation with a
combination of saturated FFA and PUFA. Wei et al. re-
ported that co-incubation with oleate reduced or prevented
the induction of ER stress and cell death caused by palmi-
tate [24]. The authors suggested that the phenomenon may
be attributable to alternations in the trafficking of saturated
fatty acids away from the ER membrane in the presence
of unsaturated fatty acids. Another study showed that co-
incubation of palmitate and 125 μM linoleate significantly
decreased apoptosis, compared to palmitate treatment
alone [33]. Meanwhile, the authors of the latter study
also mentioned that the effect was not observed with a dose
of 250 μM linoleate, indicating the dose-dependent effect of
unsaturated FFA. Anyhow, these data may offer a positive
synergistic effect of unsaturated fatty acids under conditions
of co-incubation, similar to the results in our study.
It is recommended to take saturated fat <10% of the total
caloric intake for the improvement of plasma lipid levels
[34]. As for the PUFA, supplementation with pharmaco-
logical doses of n-3 fatty acids (>2–3 g/day) reduces trigly-
ceride levels, but a higher dosage may increase low-densitylipoprotein cholesterol [34,35]. Effect of n-3 fatty acids on
the event of ischemic heart disease may be controversial
[21,36]. Meanwhile, a recent evidence has shown that the
consumption of at least 5% to 10% of energy from omega-6
PUFAs reduces the risk of coronary heart disease relative to
lower intakes, and suggested that higher intakes appear to
be safe and may be even more beneficial [37]. Although it
has been considered that care should be taken to achieve a
high n-6 : n-3 ratio in the diet and a ratio "1-4 : 1" of n-6 to
n-3 in the diet may be within the healthy range [38], not
enough data are available to make a recommendation re-
garding the optimal n-3/n-6 fatty acid ratio at present [34].
In summary, the current study has shown the potent
anti-inflammatory effect of linoleate via JNK/NFkB path-
ways which are closely involved in the pathophysiology
of NASH. Unfortunately, however, the study condition
may not be physiological with relatively high concentra-
tion of FFA. Further study may be needed to unveil the
role of FFA comprehensively, resulting in a future rec-
ommendation for dietary management.
Methods
Cell culture
Huh7 cells and HepG2, a human hepatoma cell line, were
used for the study. They were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with
10% heat-activated fetal bovine serum, 100 IU/ml
penicillin and 100 μg/ml streptomycin.
FFA treatment
FFA, palmitate and linoleate, were purchased from Sigma
Chemical Company (St. Louis, MO). Each fatty acid was
complexed with 5% bovine serum albumin and incu-
bated with the cells at final concentrations of 100–
1000 μM. FFA treatment was performed by palmitate
(1 to 18 h, 100–800 μM) or linoleate alone (9 h, 100–
1000 μM), or co-incubation with both of them (9 h,
palmitate 500 μM and linoleate 100-1000 μM).
Staining with Oil Red O
Accumulation of fatty acids was detected by staining
with Oil Red O (Wako, 154–02072). Huh7 cells were in-
cubated in the 6-well plates overnight and treated with
FFA. Dishes with control cells (cells without FFA treat-
ment) and FFA-treated cells were washed with phos-
phate buffered saline (PBS) and fixed in 10% formalin.
After washing by PBS, Oil Red O was added.
Cell viability
The cell viability was determined using the CellTiter
96 AQueous One Solution Cell Proliferation Assay
(MTS, Promea, G3580). After overnight incubation in
96 well plates with 20,000 cells/well, the cells were
washed twice with PBS and treated with FFA for 9
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6:1 ratio of medium to MTS solution and optical den-
sities were measured at 490 nm after 2 hr incubation.
The viability was expressed as a ratio (%) of FFA-
treated cells to control (untreated cells).
Human IL-8 Assay
IL-8 was measured in cell-free culture supernatants
using highly specific ELISA kit purchased from Dia-
clone SAS (Besancon Cedex, France), according to the
manufacturer’s protocol.
Quantification of lipid accumulation
Accumulated lipid was quantitatively assessed using Stea-
tosis Colorimertic Assay kit (Cayman Chemical Company,
MI). After overnight incubation of 10,000 cells/well in 96
well plates, the cells were washed twice with PBS and
treated with FFA. The 9 h-treated cells were stained ac-
cording to the manufacture’s protocol, and lipid accumu-
lation was determined by the absorbance at 490 nm. The
lipid accumulation was expressed as a ratio of FFA-treated
cells to control (untreated cells).
Real-time quantitative reverse transcription polymerase
chain reaction
Total cellular RNA was extracted using TRIzol reagent
according to the manufacturer’s protocol (Invitrogen,
Carlsbad, CA). Single-strand cDNAs were synthesized
from 2 μg total RNA in a 20 μL reaction (SuperScript®
VILO™, cDNA Synthesis Kit, Invitrogen). Polymerase
chain reactions (PCR) were performed using cDNA,
SYBR green (Platinum® SYBR® Green qPCR SuperMix-
UDG with ROX, Invitrogen) and primers for IL8,
TNFα, and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), purchased from Takara Bio (Tokyo, Japan;
Table 1). Reactions were run in triplicate and data were
calculated as the change in cycle threshold (ΔCT) for
the target gene relative to the ΔCT for GAPDH (en-
dogenous control).
Protein extraction and western blot analysis
Cell lysates were centrifuged at 12,000 g for 15 min and
proteins in the supernatants were used for western blot-
ting to detect cleaved caspase-3. Cytoplasmic extractionTable 1 Primers for quantitative polymerase chain reaction






Reverse TGGTGAAGACGCCAGTGGAwas conducted using NE-PER®Nuclear and Cytoplasmic
Extraction Reagents (Thermo scientific, Pierce Bio-
technology, Inc., Rockford, IL) with protease inhibitor
and phosphatase inhibitor (Sigma Chemical Company,
St. Louis, MO). Cytoplasmic extracts of the cells were
used for western blotting to detect phospho-c-Jun N-
terminal kinase (pJNK), total JNK (tJNK) and IkBα.
Proteins were separated using 4% -12% NuPAGE®
Novex Bis-Tris Mini Gels (Invitrogen) and were trans-
ferred to a nitrocellulose membrane for 1.5 hr at 40 V
using a western blot apparatus (Invitrogen). After over-
night incubation with primary antibody, the membranes
were washed and were incubated with horseradish
peroxidase-conjugated secondary antibodies (Pierce
Biotechnology, Inc., Rockford, IL).
Proteins were detected with an enhancement using
SuperSignal chemiluminescence reagent (Pierce) and a
LAS-4000UV (Fuji Film, Tokyo, Japan). Primary anti-
body (Cleaved Caspase-3, IkBα, pJNK, tJNK), secondary
antibody and β-actin were purchased from Cell Signaling
(Beverly, MA).Statistical analysis
Continuous variables were compared by the Student’s t-
test or Fisher’s Protected Least Significant Difference
test. P-values less than 0.05 were considered statistically
significant in all analyses. Statistical analysis was per-
formed using the Dr. SPSS software package (version
11.0 J for Windows; SPSS Inc., Chicago, Illinois, USA).Ethical approval
The study protocol was approved by the Ethical Com-
mittee of Chiba University.
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